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Abstract
Background: A key objective in many microarray association studies is the identification of individual genes
associated with clinical outcome. It is often of additional interest to identify sets of genes, known a priori to have
similar biologic function, associated with the outcome.
Results: In this paper, we propose a general permutation-based framework for gene set testing that controls the
false discovery rate (FDR) while accounting for the dependency among the genes within and across each gene set.
The application of the proposed method is demonstrated using three public microarray data sets. The performance
of our proposed method is contrasted to two other existing Gene Set Enrichment Analysis (GSEA) and Gene Set
Analysis (GSA) methods.
Conclusions: Our simulations show that the proposed method controls the FDR at the desired level. Through
simulations and case studies, we observe that our method performs better than GSEA and GSA, especially when
the number of prognostic gene sets is large.
Background
One of the primary objectives in microarray association
studies is the identification of individual genes that are
associated with clinical endpoints such as disease type,
toxicity or time to death. It is also of interest to examine
the association between known biological categories or
pathways and outcome. To this end, gene sets a priori
believed to have similar biological functions from data-
bases including KEGG [1] and Gene Ontology [2] are
used. In recent years, a number of statistical methods
have been proposed for the identification of significant
genesets based on microarray experiments. Ackerman
and Strimmer [3] list 36 methods, including [4-13],
while outlining a general framework for formulating the
hypothesis and analysis method for gene set inference.
In this paper, we propose a gene set analysis frame-
work that utilizes classical theory for estimating equa-
tions to assess the association between each gene set
and the outcome of interest. One of the statistical chal-
lenges in this setting is that there is dependency within
each gene set, by virtue of coregulated genes belonging
to the same gene set, as well as dependency across the
gene sets since gene sets are not mutually exclusive.
Our method will account for both intra-gene set and
inter-gene set dependencies. Furthermore, given the
large number of gene sets, one has to address the issue
of multiple testing. The sampling distribution of our
proposed procedure is approximated using permutation
resampling to simultaneously address the dependency
and multiple testing issues by controlling the false dis-
covery rate (FDR; [14]). In the framework described by
Ackerman and Strimmer [3], gene set analysis methods
are broadly categorized as univariate or as global and
multivariate procedures. Generally speaking, our method
belongs to the latter category. The novelty of our pro-
posed approach is that it leverages the flexibility of esti-
mating equations to conduct inference for a variety of
endpoints including binary, continuous, censored or
longitudinal outcomes.
After presenting the theoretical and computational
details for the proposed method, we summarize the
results from a simulation study evaluating its statistical
properties. We then apply the proposed method to ana-
lyze a number of microarray data sets. Finally, we pro-
vide a brief discussion to compare the performance of
our method to those of two other methods: GSEA [6]
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transcripts on microarrays as genes, even though this
may not be technically correct.
All analyses are carried out using the R statistical
e n v i r o n m e n t[ 1 5 ] .T h ec o d ei sa v a i l a b l ef r o mh t t p : / /
www.duke.edu/~is29/GeneSet. Generalized inverses are
computed using the pinv function from the maanova
[16] extension package. The inverse of linear shrinkage
covariance matrix is computed using invcov.shrink
function in corpcor [17] extension package. The R
extension packages R-GSEA[6] and GSA[18] are used to
implement the GSEA and GSA methods respectively.
The qvalue[19] extension package is used for calculat-
ing FDR adjusted P-values. For gene set and probe set
annotation, Bioconductor [20] annotation packages (e.g.,
hu6800.db[21]) and Molecular Signature Database
(MSigD; http://www.broad.mit.edu/gsea) annotation files
are used.
Methods
In these discussions, we will assume that RNA expres-
sion levels for m genes have been measured for n
patients. Let us denote the set of genes on the microar-
ray by G ={ G1, ..., Gm}. For patient i(= 1, ..., n), let yi
denote the clinical outcome and zij denote the measured
gene expression level for Gj.L e tGj ⊥ Y denote that
expression of gene j is not associated with outcome. For
each gene the marginal inference of interest will be
canonically presented as testing Hj : Gj ⊥ Y versus
¯ Hj : Gj  ⊥ Y.
Suppose that for gene j, the hypotheses of indepen-
dence can be quantified using a parameter say θj.W e
assume that θj =0i n d i c a t e st h a tGj and the outcome
are independent. Thus, the hypotheses of interest can be
expressed as testing Hj : θj ≠ 0a g a i n s t ¯ Hj : θj  =0 .W e
consider testing these marginal hypotheses within the
context of general estimating functions, which for large
n, are expressible in the form
Uj(θj)=
n  
i=1
Uij(θj),
where Uij(θj) is a function of the data for subject i
only so that U1j , ...,Unj are independent. The corre-
sponding test statistic for Hj will be Uj(0). Let μij(θj)=E
(Uij)a n dμj(θj)=
 n
i=1 μij(θj).I fE{Uj(θ)} is a smooth
function and E{Uj(θ)} = 0 has a unique solution, then
the solution   θj to Uj(θ) = 0 is a consistent estimator of
θj. The family of score statistics [22] is a special case of
this type of estimating equation.
A gene set is defined as a subset of G. We will assume
that there are K pre-specified gene sets say G1,...,GK
based on a given annotation database such as KEGG or
GO. Note that G∗ := G1 ∪ ... ∪ GK is usually a proper
subset of G as not all genes are annotated. Let mk (k =
1, ..., K) denote the number of genes in gene set Gk.W e
consider a gene set to be associated with the outcome
of interest if at least one of its member genes is asso-
ciated with the outcome. Let Gk⊥Y denote that gene set
Gk is not associated with the outcome Y. The hypotheses
of interest from gene set k can then be denoted as test-
ing Hk = Gk⊥Y versus ¯ Hk : Gk   ⊥Y.
For notational convenience, for the remainder of this
section we will focus on the first gene set G1 and assume
that it consists of the first m1 genes, G1,...,Gm1.T h e n
the hypotheses of interest can be presented as testing
H1 = ∩
m1
j=1Hj against ¯ H1 = ∪
m1
j=1 ¯ Hj.F o rt e s t i n gt h i s
hypothesis, consider the vector U1 =( U1,...,Um1)T,o f
the first m1 marginal statistics, which is approximately
normal with marginal means μj(θj) and co-variances sjj’
(j, j’ = 1, ..., m1). These quantities can be consistently
estimated by ˆ μj = μj(  θj) and
ˆ σjj  =
n  
i=1
(Uij −ˆ μij)(Uij  −ˆ μij ),
respectively, where ˆ μij = μij(  θj).L e tσjj = σ2
j and
ˆ σjj = ˆ σ2
j .
In the marginal testing setting, we have μj(0) = 0
under Hj,s ow er e j e c tHj in favor of ¯ Hj if the realized
value of U2
j
 
ˆ σ2
j is large. The test statistic U2
j
 
ˆ σ2
j has an
asymptotic c
2 distribution with 1 degree of freedom
under the null distribution. For gene set G1 we will con-
sider the test statistic
W1 = UT
1V−1
1 U1,
where V1 =(ˆ σjj )m1×m1.I fn is large and m1 <n, the dis-
tribution of W1 under H1 is approximately c
2 with m1
degrees of freedom. Similarly, we can compute Uk, Vk
and Wk for any gene set Gk.
In many cases, the sample size for a microarray study
may not be large enough for the null sampling distribu-
tion to be well approximated by the theoretical limiting
distribution. To address this issue, we propose calculat-
ing the P-values by approximating the exact null sam-
pling distribution using permutation resampling. Note
that the permutation distribution is generated under the
hypothesis H1 ∩ ... ∩ HK. That is, none of the K gene
sets are associated with the outcome. This hypothesis is
equivalent to the hypothesis ∩jHj (i.e., none of the genes
are associated with outcome). Note that the latter inter-
section is restricted to G*, the set of annotated genes. A
permutation replicate sample is obtained by randomly
shuffling the the clinical outcomes {y1, ..., yn} while hold-
ing the gene expression matrix in place. This ensures
that the intra-gene dependency structure is preserved
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the outcome.
If mk is large, Vk many not be reliably inverted
numerically and, in the case where it exceeds n,i sn o t
invertible. For these cases, we consider the Moore-Pen-
rose (MP) generalized inverse or the inverse of the lin-
ear shrinkage covariance matrix estimate VLW
[13,23-25]. Here, we remark that the Hotelling’st e s t s
with the MP generalized inverse (g-inverse) and that
with the inverse of VLW have been previously studied
[13,23]. The MP g-inverse (of the sample covariance
matrix) uses V−
k = PkD−1
k PT
k to derive a test statistic
Wk = UT
kV−
k Uk,w h e r ePk is the eigen matrix and
D−1
k =d i a g( 1
 
ν1,...,1
 
νd,0,...,0), ν1, ..., νd are the d
positive eigenvalues of Vk. The asymptotic distribution
of Wk when mk is larger than n has been investigated
extensively (e.g., [26-28]). The linear shrinkage estimate
(LW) of V is VLW = lV +( 1-l)E,w h e r eE is a well
conditioned target matrix and l is the tuning parameter.
The tuning parameter l is chosen to minimize the Fro-
benius risk along with several candidates of target
matrices [24,25].
Two-Sample Tests
Suppose that there are two groups with ng subjects in
group g(= 1, 2), n = n1 + n2.L e tzgi =( zgi1,. . . ,zgim)
T
denote the gene expression measurements from subject
i(= 1, ..., ng) in group g(= 1, 2), and ¯ zk = n−1
g
 n
i=1 zgi the
vector of sample means. Kong et al. [10] consider the
Hotelling’s T
2 statistic
T2 =
n1n2
n
(¯ z1 −¯ z2)TS−1(¯ z1 −¯ z2),
where S =( n − 2)−1  2
g=1
 ng
i=1 (zgi −¯ zg)(zgi −¯ zg)
T is
the pooled variance-covariance matrix. For θj = E(z1ij)-
E(z2ij)a n dμij(θj)=θj, T
2 asymptotically has a χ2
m distri-
bution under H0.
For U = ¯ z1 −¯ z2, our method gives
V =
˜ S1
n1
+
˜ S2
n2
,
where ˜ Sk = n−1
g
 ng
i=1 (zgi −¯ z)(zgi −¯ z)T and
¯ z = n−1  2
g=1
 ng
i=1 zgi.S i n c eT
2 is asymptotically equiva-
lent to W = U
TV
-1U under H0, we use the more popular
Hotelling’s T
2 statistic in this paper.
As a rank test alternative to the t-test, it is easy to
show that the Wilcoxon rank sum test can be expressed
as T
2 with zgij the rank of the gene j expression level for
subject i in the pooled data {zgij,1≤ i ≤ ng, g =1 ,2 } .I n
this case, θj = P(z1ij ≥ z2ij) - 1/2 and μij(θj)=θj.
Linear Regression Case
Suppose that we want to relate the gene expression zij
for gene j with a continuous outcome yi through a linear
regression
E(yi)=aj + θjzij.
No association between y and the expression of gene j
implies that θj = 0. In this case, we use Uj =   θj, the least
square estimator of the slope θj,
Uij =
(zij −¯ zj)yi
 n
i =1 (zi j −¯ zj)
2,
and
ˆ μij =
(zij −¯ zj)(ˆ aj + θjzij)
 n
i =1 (zi j −¯ zj)
2 ,
where ¯ zj = n−1  n
i=1 zij, ¯ y = n−1  n
i=1 yi and ˆ aj = ¯ y −  θj¯ zj.
Cox Regression Case
For right-censored time to event data, the outcome
data are pairs of the form yi =( ti, δi), where ti is the
minimum of survival and censoring times, and δi is the
event indicator. Let li(t) denote the hazard function of
patient i. Then the Cox proportional hazards model
relates the expression of gene j, zij,w i t ht h es u r v i v a l
time of patient i using the model lij(t)=l0j(t)e x p ( θj
zij), where l0j(t) is an unknown baseline hazard func-
tion. We propose using the partial score statistic [29]
Uj = Uj(0), where
Uj(θj)=
n  
i=1
  ∞
0
⎛
⎝zij −
s
(1)
j (t,θj)
s
(0)
j (t,θj)
⎞
⎠dNi(t),
and s
(k)
j (t,θj)=
 n
i =1 zk
i j Yi (t)eθjzi j, Yi(t)=I(ti ≥ t)a n d
Ni(t)=δII(ti ≤ t). Let   θj denote the partial MLE of θj sol-
ving the partial score equation Uj(θ) = 0. In this case, we
have
ˆ μij =
  ∞
0
 
zij −
s(1)(t,0)
s(0)(t,0)
 
Yi(t)e
ˆ θjzijd ˆ  0j(t),
where
ˆ  0j(t)=
  t
0
 n
i=1 dNi(s)
 n
i =1 Yi (s)e
ˆ θjzi j
.
The resulting variance estimator is equivalent to the
robust estimator under the possible violation of
the proportional hazards model proposed by Lin and
Wei [30].
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Simulation Study
We investigate the performance of our proposed
method with respect to FDR control through a simula-
tion study. Let zijk denote the expression level of gene j
(= 1, ..., mk)f r o ms u b j e c ti (= 1, ..., n1 + n2)i nt h e
group g(= 1, 2) for gene set Gk. We consider the follow-
ing model:
zijk =
⎧
⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎩
siδj +
√
ρ1ak +
√
ρ2b +
√
ρ3εijk
if 1 ≤ j ≤ D,1≤ k ≤ K1,
√
ρ1ak +
√
ρ2b +
√
ρ3εijk
otherwise,
where si = 0 if subject i belongs to group 1 and si =1
otherwise, and r3 =1-r1 - r2. For gene j, δj is the
treatment effect, D is the number of prognostic genes,
K1 is the number of prognostic gene sets, ak is the gene
set effect, b is the array effect, r1 and r2 are the within
gene sets and within arrays correlation coefficients
resepctively, and εijk is the error term. The gene set
effect ak, the array effect b, and the error term εijk are
generated from independently and identically distributed
N(0, 1) random variate.
At first, we investigate the performance of the test sta-
tistic using the MP inverse generalized inverse. We con-
sider m = 1, 000 genes and n = 100 samples, each with
non-overlapping K =5 0o r2 0g e n es e t so fmk =2 0o r
50 genes, respectively, (r1, r2) = (0, 0), (0.2, 0.2) or (0.4,
0.4), D/mk = 0.2, 0.5 or 0.8, δ = 0.4 and K1 = 1 or 5. We
conduct N = 1, 000 simulations under each setting, and
approximate the null distribution of the test statistic
using B = 10, 000 random permutations for each simu-
lation. The q-values [31] are obtained from the resulting
unadjusted permutation P-values by setting l =0 . 5 .
Results are presented in Table 1 where ˆ q denotes the
empirical FDR and ˆ r1 denotes the mean number of true
rejections, i.e. the mean number of prognostic gene sets
that are discovered by testing. These results illustrate
that the proposed method accurately controls the FDR
at the desired level q*. The observed true rejection rate
is high when the proportion of prognostic genes within
each gene set is large (i.e., D/mk = 0.8).
We proceed by investigating the case with small n but
large mk. We set the sample size n = 20, and consider K
=2 0a n dmk = 50. All other parameters are identical to
those used in the simulation study reported in Table 1.
We conduct N = 500 simulations and apply the test
using both MP and LW generalized inverses. The results
reported in Table 2 show that both tests control the
FDR at the desired level q*. Similar to the results pre-
sented in Table 1, for both tests the observed true-rejec-
tion rate (ˆ r1) increases in the proportion of prognostic
genes within each gene set (D/mk). However, the test
with the LW inverse has generally higher true-rejection
rate than that with the MP generalized inverse.
We compare the performance of our method to GSEA
and GSA within the simulation framework described
above. We choose, for GSEA, the weighted Kolmogorov
Smirnov-like statistic as enrichment correlation-based
weighting, while for GSA we choose the maxmean sta-
tistic along with restandardization. The technical details
are provided in [6] and in [7] respectively.
We generate m = 1, 000 genes and n = 100 samples,
each with non-overlapping K = 50 gene sets of mk =2 0
genes, (r1, r2) = (0, 0), D/mk=1 ,a n dδ = 0.4 as in [7].
The first (n1 = 50) and second (n2 = 50) samples will
constitute the control and treatment groups respectively.
Next, we will discuss two scenarios similar to those con-
sidered by [7]:
￿ One-sided shifts: The mean expression level for the
mk = 20 genes in each of the K1 prognostic gene sets
is δ = 0.4 units higher in the treatment group.
￿ Two-sided shifts: The mean expression level for
the first 10 genes in each of the K1 prognostic gene
sets is δ = 0.4 units higher, while the mean expres-
sion level for the next 10 genes is δ =0 . 4u n i t s
lower.
Each scenario is simulated 100 times using 1000 per-
mutation replicates. The P-values for the first gene set is
s h o w na g a i n s tt h en u m b e ro fp r o g n o s t i cg e n es e t si n
Figure 1. Overall, our method gives lower mean P-values
under both scenarios. In the one-sided shift case, the
t h r e em e t h o d sa r ec o m p a r a b l ew h e nt h en u m b e ro f
prognostic gene sets is at most thirteen. For the cases
with a large number of prognostic gene sets or a two-
sided shift, our method is consistently better.
Case Studies
Two-Sample Case
We analyze two microarray data sets available from the
GSEA website http://www.broad.mit.edu/gsea. The first
data set, called the Gender data set, consists of profiles
of m = 15, 056 genes from male (n1 =1 5 )a n df e m a l e
(n2 = 17) lymphoblastoid cell lines. The second data set
consists of transcriptional pro-les of m = 10, 100 genes
from p53 positive (n1 = 17) and p53 mutant (n2 = 33)
cancer cell lines. The pathways from MSigDB are cur-
rently organized into five catalogs. We use the Positional
gene sets (C1, 319 gene sets), which correspond to each
human chromosome and each cytogentic band, for the
Gender data set and the Curated gene sets (C2, 522
gene sets), which are derived from online pathway data-
bases and publications, for the p53 data set. For the ana-
lyses, we limit our attention to gene sets which consist
of a minimum of 15 and a maximum of 500 genes. Each
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performance of our method is compared to those of
GSEA and GSA. We compare the number of prognostic
gene sets identified by each method. The analysis results
for the two data sets are shown in Figure 2. For both
data sets, our method consistently identifies more prog-
nostic gene sets than GSEA and GSA for any q-value
threshold.
Cox Regression Case
We carry out gene set analysis of the lung cancer micro-
array data set [32] using the KEGG pathway (175 gene
s e t s )p r o v i d e db yt h ehu6800.db Bioconductor
p a c k a g e .T h ed a t as e tc o n s i s t so fg e n ee x p r e s s i o n so fm
= 4, 966 genes from n =8 6s t a g eIo rI I Il u n gc a n c e r
patients. As in the analyses for the previous data sets,
we include gene sets consisting of 15 to 500 genes each
in the analysis, and use 10,000 permutations to derive
the null distribution of the test statistics. For this analy-
sis, we will compare our method to GSA only since the
R-GSEA extension package does not provide the func-
tionality for analyzing right censored data. The results
are shown in Figure 3 suggest that our method generally
identifies a larger number of prognostic gene sets com-
pared to GSA.
Table 1 Empirical FDR and mean true rejections
q* = 0.01 q* = 0.05 q* = 0.1 q* = 0.2
(mk, K) K1 D/m (r1, r2) ˆ q ˆ r1 ˆ q ˆ r1 ˆ q ˆ r1 ˆ q ˆ r1
(50,20) 1 0.2 (0, 0) 0.010 0.10 0.063 0.25 0.105 0.35 0.189 0.46
(0.2, 0.2) 0.015 0.08 0.053 0.28 0.128 0.38 0.231 0.45
(0.4, 0.4) 0.013 0.12 0.045 0.25 0.087 0.36 0.215 0.47
0.5 (0, 0) 0.011 0.72 0.060 0.88 0.107 0.95 0.220 0.98
(0.2, 0.2) 0.015 0.71 0.051 0.89 0.122 0.94 0.212 0.97
(0.4, 0.4) 0.005 0.74 0.071 0.89 0.115 0.94 0.266 0.95
0.8 (0, 0) 0.013 0.97 0.057 1.00 0.106 1.00 0.215 1.00
(0.2, 0.2) 0.013 0.98 0.065 1.00 0.138 1.00 0.235 1.00
(0.4, 0.4) 0.018 0.97 0.078 1.00 0.124 1.00 0.253 1.00
5 0.2 (0, 0) 0.025 0.72 0.067 1.70 0.136 2.51 0.239 3.56
(0.2, 0.2) 0.009 0.68 0.056 1.79 0.127 2.63 0.235 3.59
(0.4, 0.4) 0.011 0.74 0.058 1.82 0.118 2.46 0.232 3.55
0.5 (0, 0) 0.007 4.44 0.058 4.94 0.124 4.97 0.227 5.00
(0.2, 0.2) 0.013 4.46 0.056 4.90 0.118 4.97 0.214 4.99
(0.4, 0.4) 0.012 4.44 0.074 4.87 0.137 4.96 0.239 5.00
0.8 (0, 0) 0.012 4.99 0.066 5.00 0.120 5.00 0.235 5.00
(0.2, 0.2) 0.011 5.00 0.056 5.00 0.105 5.00 0.200 5.00
(0.4, 0.4) 0.011 4.98 0.053 5.00 0.101 5.00 0.218 5.00
(20,50) 1 0.2 (0, 0) 0.008 0.04 0.055 0.13 0.092 0.21 0.185 0.25
(0.2, 0.2) 0.015 0.04 0.051 0.10 0.128 0.15 0.219 0.21
(0.4, 0.4) 0.005 0.06 0.050 0.10 0.110 0.14 0.198 0.22
0.5 (0, 0) 0.013 0.45 0.048 0.63 0.118 0.72 0.240 0.82
(0.2, 0.2) 0.010 0.43 0.077 0.64 0.122 0.72 0.223 0.80
(0.4, 0.4) 0.010 0.49 0.072 0.68 0.112 0.76 0.214 0.83
0.8 (0, 0) 0.010 0.86 0.043 0.97 0.113 0.99 0.222 0.99
(0.2, 0.2) 0.015 0.89 0.048 0.98 0.115 0.98 0.208 0.98
(0.4, 0.4) 0.013 0.86 0.052 0.96 0.102 0.99 0.201 1.00
5 0.2 (0, 0) 0.013 0.31 0.054 0.76 0.121 1.08 0.210 1.64
(0.2, 0.2) 0.010 0.28 0.039 0.57 0.102 0.89 0.224 1.56
(0.4, 0.4) 0.015 0.18 0.062 0.57 0.103 0.94 0.195 1.59
0.5 (0, 0) 0.011 3.03 0.055 4.03 0.107 4.43 0.201 4.75
(0.2, 0.2) 0.008 3.01 0.054 4.11 0.104 4.44 0.218 4.77
(0.4, 0.4) 0.016 3.22 0.058 4.16 0.103 4.50 0.203 4.72
0.8 (0, 0) 0.010 4.74 0.054 4.91 0.112 4.95 0.224 4.99
(0.2, 0.2) 0.011 4.76 0.054 4.94 0.111 4.97 0.212 4.98
(0.4, 0.4) 0.012 4.73 0.054 4.93 0.110 4.96 0.201 4.99
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For the Gender data set, at the FDR level of q* = 0.2, our
method identifies 8 gene sets compared to only 4 for the
other two methods [see Additional file 1]. There are 4
prognostic gene sets identified in common among the
three methods, consisting of gene sets found on ChrY,
ChrYp11, ChrYq11, and ChrXp22. Our method identifies
4 other gene sets not identified by the other two methods,
which include gene sets for ChrX, ChrXp11, Chr3q25, and
Chr6q25. Genes expressed on the Y chromosome are
expected to be differentially expressed between genders,
while gene expression from the X chromosome is more
similar between genders due to X chromosome inactiva-
tion in females [33,34]. However, ChrXp22 and ChrXp11
gene sets have been previously been shown to be overre-
presented in females likely caused by escape of X inactiva-
tion [35]. Furthermore, several genes within the Chr3q25
and Chr6q25 gene sets have also been shown to be differ-
entially expressed between males and females, including
ACAT2 [36], MAP3K4 [37], NOX, PTX3 [38], SGEF, and
SOD2 [39]. Thus, our method for identifying overrepre-
sented genes in gene set lists can provide biologically rele-
vant and important information that may be overlooked
by other common methods such as GSA and GSEA.
Table 2 Empirical FDR and mean true rejections on simulation data with small n large p values
q* = 0.01 q* = 0.05 q* = 0.1 q* = 0.2
K1 D/mk (r1, r2) method ˆ q ˆ r1 ˆ q ˆ r1 ˆ q ˆ r1 ˆ q ˆ r1
1 0.2 (0, 0) MP 0.0160 0.004 0.0633 0.018 0.1102 0.036 0.2328 0.058
LW 0.0060 0.018 0.523 0.040 0.1022 0.060 0.2294 0.098
(0.2 0.2) MP 0.0100 0.006 0.0593 0.010 0.1145 0.022 0.2325 0.042
LW 0.0180 0.006 0.0563 0.020 0.1058 0.036 0.2249 0.084
(0.4 0.4) MP 0.0180 0.008 0.0590 0.020 0.1133 0.032 0.2182 0.054
LW 0.0100 0.010 0.0503 0.032 0.1087 0.048 0.2387 0.094
0.5 (0, 0) MP 0.0120 0.024 0.0650 0.068 0.1138 0.100 0.2016 0.162
LW 0.0210 0.078 0.0652 0.160 0.1189 0.230 0.2303 0.330
(0.2 0.2) MP 0.0300 0.024 0.0720 0.072 0.1269 0.106 0.2608 0.170
LW 0.0200 0.084 0.0823 0.154 0.1467 0.222 0.2658 0.316
(0.4 0.4) MP 0.0290 0.038 0.0920 0.072 0.1359 0.112 0.2161 0.184
LW 0.0150 0.070 0.0747 0.168 0.1300 0.228 0.2444 0.338
0.8 (0, 0) MP 0.0150 0.084 0.0667 0.136 0.1261 0.178 0.2534 0.258
LW 0.0070 0.240 0.0520 0.404 0.1199 0.508 0.2179 0.618
(0.2 0.2) MP 0.0260 0.068 0.0563 0.142 0.1147 0.198 0.2341 0.276
LW 0.0220 0.234 0.0603 0.420 0.1054 0.516 0.2095 0.622
(0.4 0.4) MP 0.0153 0.068 0.0738 0.138 0.1299 0.176 0.2548 0.258
LW 0.0270 0.274 0.0607 0.434 0.1129 0.512 0.2118 0.636
5 0.2 (0, 0) MP 0.0080 0.022 0.0503 0.094 0.0924 0.194 0.1817 0.386
LW 0.0120 0.066 0.0443 0.188 0.0933 0.344 0.1883 0.726
(0.2 0.2) MP 0.0180 0.024 0.0683 0.084 0.1030 0.138 0.2140 0.364
LW 0.0170 0.054 0.0642 0.144 0.1028 0.288 0.2125 0.646
(0.4 0.4) MP 0.0060 0.040 0.0350 0.078 0.0848 0.158 0.1969 0.304
LW 0.0150 0.072 0.0446 0.192 0.0762 0.328 0.1761 0.668
0.5 (0, 0) MP 0.0143 0.158 0.0479 0.402 0.0990 0.608 0.2144 1.062
LW 0.0140 0.442 0.0626 1.148 0.1221 1.734 0.2131 2.586
(0.2 0.2) MP 0.0157 0.148 0.0586 0.418 0.0974 0.662 0.2090 1.128
LW 0.0127 0.452 0.0646 1.162 0.1076 1.796 0.2165 2.644
(0.4 0.4) MP 0.0160 0.150 0.0602 0.418 0.0978 0.678 0.2062 1.142
LW 0.0108 0.498 0.0572 1.154 0.1134 1.680 0.2226 2.548
0.8 (0, 0) MP 0.0193 0.468 0.0662 1.006 0.1194 1.452 0.2320 2.054
LW 0.0216 1.660 0.0609 3.044 0.1220 3.702 0.2385 4.286
(0.2 0.2) MP 0.0127 0.478 0.0567 1.036 0.1130 1.440 0.2257 2.156
LW 0.0145 1.654 0.0506 2.970 0.1157 3.670 0.2269 4.278
(0.4 0.4) MP 0.0200 0.510 0.0587 1.020 0.1080 1.468 0.2163 2.164
LW 0.0201 1.772 0.0729 3.066 0.1303 3.662 0.2350 4.234
Here, n = 20, mk = 50, and K = 20.
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Figure 1 Mean P-value against the number of prognostic gene sets.
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Figure 2 The number of prognostic gene sets, at a given q-value threshold, identified by all three methods are shown for the Gender
and p53 data sets.
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Page 7 of 10For the p53 data set, at the same FDR level, our method
identifies 87 prognostic gene sets while GSA and GSEA
identify 5 and 9 prognostic gene sets, respectively [see
Additional file 1]. There are 5 prognostic gene sets com-
mon among the three methods, including the p53 path-
way, hsp27 pathway, radiation sensitivity pathway,
ceramide pathway, and the ras pathway. However, our
method identifies 78 gene sets not identified by the other
two methods. Additional file 1 also provides a list of gene
sets that are identified only by our method. p53 is a tumor
suppressor protein that is activated in response to DNA
damage. p53 can induce growth arrest by halting the cell
cycle at the G1/S phase transition to allow DNA repair or
it can induce apoptosis if the DNA damage cannot be
repaired. p53 acts as a transcription factor regulating the
expression of many genes involved in its functions [40].
Thus many of the gene sets identified by our method can
be directly linked to p53 functions, such as cell cycle
arrest, ATM pathway, tumor suppressor, bcl2 family and
network, death pathway, etc [40]. Additionally, several
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Figure 3 The number of prognostic gene sets, at a given q-value threshold, identified by our and the GSA method are shown for the
Beer Lung Cancer data set.
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Page 8 of 10cytokine and growth factor signaling pathways are repre-
sented in our list of gene sets differentially expressed
between p53 positive and mutant cell lines, including the
IL-4 [41], EGF [42], NGF [43], CXCR4 [44], IL-7 [45], and
PDGF [46] pathways, which have all shown roles for p53
in their regulation and signaling. The method that we
describe here for identifying prognostic gene sets can pro-
vide a more inclusive list of gene sets that provide further
insight into the biology of two sample case studies from
microarray experiments.
Conclusion
In this paper, we have presented a multiple testing pro-
cedure to identify prognostic gene sets from a microar-
ray experiment correlated with common types of binary,
continuous and time to event clinical outcomes. We cal-
culate the marginal P-values using a permutation
method accounting for dependency among the genes
within and across each gene set, and account for multi-
ple testing by controlling the FDR. Our simulations
show that our proposed method controls the FDR at the
desired level. Through extensive simulations and real
case studies, we observe that our method performs bet-
ter than GSEA and GSA, especially when the number of
prognostic gene sets is large.
Additional material
Additional file 1: Results from gene set analyses for the Gender and
p53 data sets. This file contains two tables. Tables 1 and 2 summarize
gene set analysis results based on three methods for the Gender and
p53 data sets respectively.
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